Willin/FRMD6 Mediates Mitochondrial Dysfunction Relevant to Neuronal Aβ Toxicity

Cells. 2022 Oct 6;11(19):3140. doi: 10.3390/cells11193140.

Abstract

Willin/FRMD6 has been reported as a potential Alzheimer's disease (AD) risk gene in a series of genome-wide association and neuroimaging studies; however, the mechanisms underlying its potential role in AD pathogenesis remain unknown. Here, we demonstrate the direct effects of Aβ on Willin/FRMD6 expression and position mitochondrial oxidative stress as a novel potential mechanism underlying the role of Willin/FRMD6 in AD pathogenesis. Specifically, using mouse hippocampal HT-22 cells and primary mouse neurons, we show that Aβ induces downregulation of Willin/FRMD6 protein expression. Furthermore, we demonstrate that Willin/FRMD6 knockdown leads to mitochondrial dysfunction and fragmentation, as well as upregulation of ERK1/2 signaling, both of which are reported to be key early features of AD pathogenesis. Importantly, increasing Willin/FRMD6 expression was able to rescue Aβ-induced abnormalities in mitochondrial morphology, function, and energetics. Thus, enhancing Willin/FRMD6 expression holds potential as a therapeutic strategy for protecting against Aβ-induced mitochondrial and neuronal dysfunction.

Keywords: Alzheimer’s disease; ERK signaling; Willin/FRMD6; mitochondrial dysfunction; neurodegeneration; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides* / metabolism
  • Animals
  • Genome-Wide Association Study*
  • Mice
  • Mitochondria / metabolism
  • Neurons / metabolism
  • Signal Transduction

Substances

  • Amyloid beta-Peptides

Grants and funding

This study was supported by the EPSRC (EP/P030017), Alzheimer’s Research UK, the Rosetrees Trust, and the China Scholarship Council.